Biohaven Ltd.(BHVN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BHVN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Biohaven Ltd. (BHVN), a Healthcare sector company. BHVN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Biohaven Ltd. reports net income of $-130.5M, free cash flow of $-149.9M. Top institutional holders of BHVN by reported 13-F value include JANUS HENDERSON GROUP PLC, BlackRock,, SUVRETTA CAPITAL MANAGEMENT,, based on the most recent SEC filings. BHVN trades on the NYSE exchange and files with the SEC under CIK 1935979. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BHVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Biohaven Ltd. directly from SEC EDGAR.
Net Income
Q1 2026
$-130.5M
Free Cash Flow
Q1 2026
$-149.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+12.7% YoYOperating Income
+15.8% YoYEPS (Diluted)
+26.1% YoYTotal Assets
-26.6% YoYOp. Cash Flow
-4.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-738.8M +12.7% | $-846.4M -107.4% | $-408.2M +28.4% | $-570.3M -380.6% | $-118.7M | — |
| Operating Income | $-745.4M +15.8% | $-885.1M -103.0% | $-436.1M +23.2% | $-567.9M -396.0% | $-114.5M | — |
| EPS (Diluted) | $-6.86 +26.1% | $-9.28 -62.0% | $-5.73 +55.1% | $-12.75 -323.6% | $-3.01 | — |
| Total Assets | $451.4M -26.6% | $615.1M +19.9% | $513.2M -22.5% | $661.8M | — | — |
| Operating Cash Flow | $-609.4M -4.6% | $-582.5M -75.6% | $-331.7M -11.4% | $-297.7M -291.9% | $-76.0M | — |
AI Insight: BHVN Ratio Trends
Data is too sparse to identify meaningful trends, with only one ROE data point showing -176.5% in Q4 2024.
• ROE was deeply negative at -176.5% in Q4 2024, the only available profitability metric.
⚠ Complete absence of operating margin, net margin, and return metrics across most quarters limits visibility.
Get alerted when BHVN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Biohaven Ltd. including:
Top Institutional Holders of BHVN
JANUS HENDERSON GROUP PLC
$148.2M17,534,612 shBlackRock, Inc.
$94.9M11,222,407 shSUVRETTA CAPITAL MANAGEMENT, LLC
$87.0M10,286,937 shSTIFEL FINANCIAL CORP
$84.1M9,940,885 shSTATE STREET CORP
$56.0M6,618,803 shINFINITUM ASSET MANAGEMENT, LLC
$52.9M6,250,000 shTCG Crossover Management, LLC
$39.2M4,631,317 shRoyalty Pharma Sub-Manager, LLC
$24.8M2,936,507 shD. E. Shaw & Co., Inc.
$24.1M2,847,193 shGEODE CAPITAL MANAGEMENT, LLC
$23.4M2,767,763 sh
| Fund | Value | Shares |
|---|---|---|
| JANUS HENDERSON GROUP PLC | $148.2M | 17,534,612 |
| BlackRock, Inc. | $94.9M | 11,222,407 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $87.0M | 10,286,937 |
| STIFEL FINANCIAL CORP | $84.1M | 9,940,885 |
| STATE STREET CORP | $56.0M | 6,618,803 |
| INFINITUM ASSET MANAGEMENT, LLC | $52.9M | 6,250,000 |
| TCG Crossover Management, LLC | $39.2M | 4,631,317 |
| Royalty Pharma Sub-Manager, LLC | $24.8M | 2,936,507 |
| D. E. Shaw & Co., Inc. | $24.1M | 2,847,193 |
| GEODE CAPITAL MANAGEMENT, LLC | $23.4M | 2,767,763 |
More Healthcare Companies
View all Healthcare →Put BHVN on your watchlist
Track score changes the day Biohaven Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BHVN a good stock to buy?
13F Pro's AI-powered analysis of Biohaven Ltd. (BHVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BHVN are available on the BHVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BHVN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BHVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Biohaven Ltd.'s investment landscape.